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Abstract
Introduction: Non-alcoholic fatty liver disease (NAFLD) is becoming a major health problem worldwide.
Inflammation plays an important role in disease pathogenesis and recent studies have shown a potential role for
the neutrophil serine proteases (NSPs) proteinase-3 (PR3) and neutrophil elastase (NE) in NAFLD as well as an
imbalance between NSPs and their natural inhibitor alpha-1 antitrypsin (AAT). The aim of this study was to
investigate whether PR3 and NE plasma concentrations are associated with NAFLD and/or type 2 diabetes.
Methods: To explore this hypothesis we used several cohorts: a cohort of 271 obese individuals with liver steatosis,
a cohort of 41 patients with biopsy-proven NAFLD, a cohort of 401 obese type 2 diabetes patients and a cohort of
205 lean healthy controls; and measured PR3 and NE plasma concentrations. In addition, we measured AAT plasma
concentrations in order to investigate if the ratios between NSPs and their natural inhibitor were altered in NAFLD
and type 2 diabetes when compared to healthy controls.
Results: Our data shows an increase in PR3 and NE concentrations and a decrease in AAT concentrations in obese
patients when compared to controls. Moreover, PR3 plasma concentrations are increased in patients with liver
steatosis. Furthermore, PR3 and NE concentrations in the liver are associated with the advanced stages of NAFLD
characterized by NASH and/ or liver fibrosis. Additionally, PR3 and NE concentrations were up-regulated in patients
with type 2 diabetes when compared to lean and obese controls.
Conclusion: We conclude that circulating levels of NSPs associate with obesity-related metabolic disorders. Further
research is needed to clearly establish the role of these proteases and investigate whether they could be used as
non-invasive markers for NAFLD and/or type 2 diabetes.
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Background
Non-alcoholic fatty liver disease (NAFLD) has a preva-
lence of approximately 25% among the global population
(Younossi et al. 2016), and is increasing rapidly, in paral-
lel with the increasing prevalence of obesity. NAFLD is
highly associated with the metabolic syndrome, a
medical condition characterized by the combination of
abdominal obesity, high blood pressure, insulin resist-
ance and dyslipidemia (Dietrich and Hellerbrand 2014;
Asrih and Jornayvaz 2015).
The disease can range from plain liver steatosis to a
more severe form called non-alcoholic steatohepatitis
(NASH) characterized by liver inflammation and hepato-
cyte ballooning, which can further progress into liver
fibrosis, cirrhosis and even hepatocellular carcinoma
(Machado and Cortez-Pinto 2014). Although the patho-
genesis of NAFLD is not completely understood, it is
known that inflammation plays an important role in dis-
ease development and progression. The pro-inflammatory
cytokine IL-1β (Interleukin-1β) is one of the key cytokines
responsible for induction and perpetuation of inflamma-
tion in the liver, thereby contributing to disease severity
(Mirea et al. 2018). IL-1β is secreted as an inactive precur-
sor and needs enzymatic processing in order to become
bioactive. The well-known enzyme available for processing
and activation of IL-1β is caspase-1, a cysteine protease
activated by the NLRP3 inflammasome protein complex.
In recent years, several studies have shown that caspase-1
and/or components of the inflammasome are involved in
NAFLD and other metabolic disorders (Dixon et al. 2012,
2013; Wan et al. 2015; Wree et al. 2014). However, it has
been reported that several other proteases are also
able to process pro-IL1β. The neutrophil serine prote-
ases (NSPs) proteinase-3 (PR3) and neutrophil elas-
tase (NE) are able to process IL-1 β to its bioactive
form independently of caspase-1-NLRP3 inflamma-
some complex (Mirea et al. 2018).
NSPs are anti-microbial peptides that are stored in the
azurophilic granules of neutrophils. Upon neutrophil
activation, they are released from the granules and can
activate cytokines in the neutrophil cytosol or in the
extracellular space. Outside the cell, NSPs are inhibited
by alpha-1 antitrypsin (AAT), a serine protease inhibitor
mainly produced by the liver (Korkmaz et al. 2010).
Although it is well-known that these NSPs are involved
in several inflammatory diseases, their role in metabolic
diseases is less investigated. However, in recent years,
several studies have shown that NE and PR3 are
important drivers of chronic inflammation leading to
metabolic disturbances in mouse models for obesity-
induced insulin resistance, type 2 diabetes and
NAFLD (Mansuy-Aubert et al. 2013; Toonen et al.
2016; Talukdar et al. 2012). Overall, these studies sug-
gest that, an imbalance between the concentrations of
NE, PR3 and their inhibitor AAT may contribute to
these metabolic disturbances.
While these findings have been mainly reported in
murine experimental models of the disease, little is
known whether NSPs are also involved in NAFLD and
related metabolic conditions in humans. The aim of this
study was to investigate whether PR3 and NE plasma
concentrations are associated with liver fat content and
the development of fatty liver disease in a cohort of 271
obese individuals with liver steatosis diagnosed by
1H-MRS (proton magnetic resonance spectroscopy).
Because some of these individuals had high alcohol
consumption and were susceptible to develop alcoholic
liver disease (ALD), another cause of fatty liver disease;
we first analyzed the relation between NSPs and liver fat
content in the whole cohort and further on we analyzed
NSPs plasma concentrations in individuals at risk to
develop NAFLD and individuals at risk to develop ALD.
Moreover, to better understand the role of NSPs in
NAFLD, we investigated a cohort of 41 individuals with
biopsy-diagnosed NAFLD. In addition, we assessed
whether circulating concentrations of neutrophil serine
proteases are associated with the development of insulin
resistance and type 2 diabetes in a well-characterized
cohort of 401 individuals with type 2 diabetes.
Material and methods
Patient cohorts
Three hundred two individuals, aged 55–80, with a BMI
(body mass index) above 27 kg/m2 were enrolled in the
300-OB study (IN-CONTROL: study of the Cardiovas-
cular research Netherlands Project). To investigate the
relation between PR3, NE and AAT plasma concentra-
tions and the development of liver steatosis we only
selected the individuals with the hepatic fat content
assessed by 1H-MRS (n = 271). Because some of the
included individuals had a high alcohol intake, we also
divided this cohort based on the alcohol intake
(European Association for the Study of the L, European
Association for the Study of D, European Association for
the Study of O 2016) in individuals at risk to develop
alcoholic liver disease and individuals at risk to develop
non-alcoholic liver disease. Furthermore, to explore the
relation between PR3, NE and AAT and the advanced
stages of NAFLD we selected a cohort of 41 patients
with biopsy-diagnosed NAFLD. Patients included in
this cohort were recruited in the context of another
clinical study regarding development of fibrosis in
NAFLD and patients’ characteristics were previously
described (Munsterman et al. 2018).
To explore the relation between PR3, NE and AAT
concentrations and the development of type 2 diabetes,
401 type 2 diabetes patients, which were part of the local
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Parelsnoer cohort type 2 diabetes (Navis et al. 2014)
(https://parelsnoer.org), were included.
In addition, 205 lean healthy individuals were included
as a control cohort for our analysis. These healthy
individuals were part of the 500 Functional Genomic
Project.
All projects were approved by the Ethical Committee
of Radboud University Medical Center, Nijmegen. Exper-
iments were conducted according to the principles
expressed in the Declaration of Helsinki. Samples of
venous blood were drawn after informed consent was
obtained.
Assessment of liver fat content
The hepatic fat content was quantified using localized
proton magnetic resonance spectroscopy (1H-MRS)
(Navis et al. 2014). A single voxel was positioned in the
right lobe of the liver. The voxel was placed outside the
biliary tree and blood vessels to avoid confounding of
the region of interest. All images from MR spectroscopy
were post-processed using the jMRUI software v3.0
package and the AMARES algorithm to determine water
(4.7 ppm) and methylene (1.3 ppm) resonance areas. The
frequency of the second peak was shifted between 10
to16 ppm and a phase correction between − 0.2 to 0.2
was performed. Intrahepatic triglyceride content was
expressed as the area of the lipid peak by the sum of the
areas of the methylene lipid peak and the water peak.
The areas were not corrected for the differences in
relaxation time between the water and lipid signals, as
we used a short echo time (20 msec). The cut-off
concentration for diagnosing liver steatosis was a total
liver fat content > 5.6% (Kroese et al. 2009). Individuals
with normal liver fat content (≤5.6%) were included as
obese controls without liver steatosis (n = 105). The
remaining 166 individuals had a liver fat content > 5.6%
and formed the liver steatosis group.
PR3, NE, AAT and hsCRP measurements
PR3, NE and AAT plasma concentrations were quanti-
fied using sandwich ELISAs (enzyme-linked immuno-
sorbent assay; cat# HK384, HK319 and HK387
respectively, Hycult Biotech, Uden, The Netherlands)
according to manufacturer’s instructions. PR3 concen-
trations were measured in plasma samples from all 271
obese individuals and 205 healthy controls. For the 401
type 2 diabetes individuals, PR3 concentrations were
measured in serum samples and values were adjusted in
order to be able to compare to concentrations measured
in plasma samples. The adjustment was realized as
follows: we measured PR3 concentrations in a subset of
12 individuals (6 from the type 2 diabetes cohort and 6
from the 271 obese cohort) for which both serum and
plasma samples were available. Results showed that
serum concentrations were 3 times higher when
compared to plasma concentrations (Additional file 1:
Figure S1). Subsequently, serum concentrations for all
type 2 diabetes individuals were corrected by a factor
3 and these values were considered equivalent to
plasma concentrations. NE and AAT concentrations
were measured in plasma samples for all cohorts.
In order to investigate the balance between NSPs
and their natural inhibitor AAT, PR3 to AAT ratio
and NE to AAT ratio were calculated by dividing
PR3, respectively NE plasma concentrations to AAT
plasma concentrations.
Because some values for PR3, NE or AAT were outside
the assay ranges, the concentrations of these proteins
could not be determined in some individuals and final
numbers of patients and controls included in the
analysis are slightly different from the numbers initially
included in the study.
High sensitive C-Reactive Protein (hsCRP) concentra-
tions were assessed by ELISA following manufacturer’s
instructions (R&D Systems, BioTechne, Minneapolis,
MN, USA).
Liver lysates measurements
Liver lysates were prepared as previously described
(Munsterman et al. 2018). PR3 and NE concentrations
were measured in liver lysates according to manufacter’s
protocol (cat# HK384, HK319 respectively, Hycult
Biotech, Uden, The Netherlands). Total protein content
was measured using BCA (bicinchoninic acid protein
assay) following manufacturer’s instructions (Compat-A-
ble BCA Protein Assay Kit, ThermoFisher Scientific).
Final PR3 and NE concentrations in the liver were calcu-
lated as ng PR3/mg protein respectively ng NE/mg
protein.
Statistical analysis
Statistical analysis was performed using IBM SPSS
Statistics 22 (IBM, Armonk, NY, USA). The data was
not normally distributed and it was natural logarithm
transformed. Given that age and BMI are confounding
factors for the development of NAFLD and type 2
diabetes, we corrected for these factors in our analysis
by ANCOVA analysis. Bonferroni post hoc test was ap-
plied to correct for multiple testing. We report here the
p-values obtained after corrections for these two con-
founding factors. The correlation between variables was
assessed by linear regression analysis using the stepwise
method. A p value ≤0.05 was considered statistically
significant. Graphs were designed using Graphpad Prism
5.0 version for Windows (Graphpad Software, La Jolla,
California, USA).
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Results
Neutrophil serine proteases plasma concentrations in
patients with liver steatosis and T2DM versus obese and
lean healthy individuals
In total, PR3, NE and AAT plasma concentrations were
measured and compared in four groups: 1) lean healthy
control group, 2) obese (without steatosis) control
group, 3) liver steatosis group and 4) type 2 diabetes
group (T2DM). No statistical differences in gender
distribution were observed between these groups. Seven
of the obese individuals without liver steatosis and 23 of
the individuals with liver steatosis had type 2 diabetes.
In order to see if the differences observed between these
two groups were independent of the presence of type 2
diabetes we additionally corrected for the presence of
this disease when comparing them; however, p-values
did not change after correction. Patients’ characteristics
of all groups are shown in Table 1. Transformed data is
available in Additional file 2: Table S1.
NSPs and AAT concentrations in patients with liver steatosis
Plasma PR3 concentrations were significantly higher in
patients with liver steatosis (p < 0.0001) when compared
to lean and obese healthy controls (Fig. 1a) whereas PR3
concentrations were similar in lean versus obese healthy
controls (Fig. 1a).
NE plasma concentrations were significantly higher in
the liver steatosis group when compared to lean healthy
controls group (p = 0.001) (Fig. 1b). NE plasma concen-
trations were also significantly higher (p = 0.019) in the
obese controls group when compared to lean healthy
controls group (Fig. 1b). No difference was observed
between NE plasma concentrations in the liver steatosis
group when compared to the obese controls group.
Regarding AAT, there was no difference in plasma
concentrations between the patients with liver steatosis
and obese healthy controls, while AAT concentrations
tended to be higher in the lean controls group (Fig. 1c).
Furthermore, we calculated PR3 to AAT and NE to
AAT ratio in order to assess the imbalance between
NSPs and their natural inhibitor in patients versus
controls. Interestingly, there was an increase in the PR3/
AAT ratio in patients with liver steatosis versus control
groups (p = 0.001) (Fig. 1d) while NE/AAT ratio was
increased in the liver steatosis group only when com-
pared to lean healthy controls group (0.02) (Fig. 1e).
Of note, PR3 and NE correlated with each other
(Additional file 3: Table S2).
Both PR3 and NE concentrations positively correlated
with hsCRP concentrations (p<0.0001) (Additional file 3:
Table S2) confirming that both PR3 and NE are released
during inflammatory status and might contribute to it.
As expected, hsCRP concentrations were significantly
lower in the lean control group when compared to the
other groups (p < 0.0001) (Fig. 1f ).
Together, this data shows that PR3 and NE concentra-
tions are increased in obesity while AAT concentrations
are decreased. Moreover, PR3 plasma concentrations
seem to be associated with the presence of liver steatosis
in our cohort.
NSPs and AAT concentrations in patients at risk to develop
ALD
In our cohort of obese individuals, some of them had
increased alcohol consumption as defined by EASL
(European Association for the study of the Liver) guide-
lines: > 30 g/day for men and > 20 g/day for women
(European Association for the Study of the L, European
Association for the Study of D, European Association for
the Study of O 2016). Therefore, we divided this cohort in
individuals at risk to develop NAFLD and individuals at
risk to develop ALD (alcoholic liver disease) based on their
alcohol consumption. Furthermore, based on the 1H-MRS
fat content we subdivided these groups in individuals with
liver steatosis and obese controls. PR3 concentrations were
significantly higher in individuals with liver steatosis when
compared to obese controls in both NAFLD risk group
(p<0.0001) (Additional file 4: Figure S2A) and ALD risk
group (p<0.0001) (Additional file 4: Figure S2B). No differ-
ence was observed for NE and AAT plasma concentrations
between these groups (Additional file 4: Figure S2C-F). All
this data suggest that PR3 is associated with the presence
of liver steatosis regardless the etiology of liver injury.
PR3 and NE concentrations in the liver are higher in
advanced histological grades of NAFLD
To investigate whether NSPs concentrations correlated
with NAFLD disease severity, we measured proteinase-3
Table 1 Characteristics of our 4 groups of patients and controls
Variable Lean controls (n = 205) Obese controls (n = 105) Liver steatosis (n = 166) Type 2 diabetes (n = 401)
Gender(M/F) 99/106 56/49 93/73 237/164
Age (years) 33 ± 14 66 ± 5 67 ± 5 69 ± 10
BMI (kg/m2) 23.17 ± 2.9 30.02 ± 2.81 31.09 ± 3.6 32.62 ± 6.5
HbA1c (mmol/mol) NA 39.41 ± 4.74 42.8 ± 8.6 63.1 ± 14.13
Liver fat content (%) NA 2.5 ± 1.3 18 ± 13 NA
Data is expressed as mean ± SD. BMI body mass index, HbA1c glycated hemoglobin A1c, NA not applicable
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and neutrophil elastase concentrations in liver lysates of
41 patients with different degrees of NAFLD severity.
General characteristics of these patients are present in
Table 2. Although not statistically significant, both PR3
and NE concentrations in the liver were higher in
advanced stages of NAFLD (Fig. 2a, b). Regarding liver fi-
brosis, a clear trend was observed between increasing PR3
concentrations in the liver and fibrosis severity (Fig. 2c). A
similar trend was observed for NE as well (Fig. 2d).
Transformed data is shown in Additional file 5: Table S3.
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Fig. 1 PR3, NE, AAT and hsCRP plasma concentrations in patients with liver steatosis and type 2 diabetes versus lean and obese controls. a PR3
plasma concentrations in patients with liver steatosis and type 2 diabetes versus lean and obese controls. b NE plasma concentrations in patients
with liver steatosis and type 2 diabetes versus lean and obese controls. c AAT plasma concentrations in patients with liver steatosis and type 2
diabetes versus lean and obese controls. d PR3 to AAT ratio in patients with liver steatosis and type 2 diabetes versus lean and obese controls.
e NE to AAT ratio in patients with liver steatosis and type 2 diabetes versus lean and obese controls. f hsCRP concentrations in patients with liver
steatosis and type 2 diabetes versus lean and obese controls. Data is represented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, NS = p > 0.05
Mirea et al. Molecular Medicine           (2019) 25:16 Page 5 of 10
These results suggest that PR3 and NE are associated
with the progression from NAFLD to NASH and liver
fibrosis. Further studies, including more samples are
warranted to clarify the role of NSPs in non-alcoholic
liver disease development and progression.
NSPs and AAT concentrations in patients with type 2 diabetes
Both PR3 and NE plasma concentrations were signifi-
cantly higher in patients with type 2 diabetes when
compared to lean healthy controls (p = 0.005) and obese
controls (p < 0.0001) (Fig. 1a, b).
Regarding AAT - plasma concentrations were
significantly higher in individuals with type 2 diabetes
when compared to obese individuals (p = 0.002) and
individuals with liver steatosis (p < 0.0001) (Fig. 1c).
Interestingly, there was no difference in PR3/AAT ratio
in patients with type 2 diabetes when compared to both
control groups (Fig. 1d). However, PR3/AAT ratio was
significantly lower in patients with type 2 diabetes when
compared to patients with liver steatosis (p < 0.0001)
(Fig. 1d) suggesting a potential specific association of
PR3 with liver steatosis. Of most importance, NE/AAT
ratio was significantly increased in patients with type 2
diabetes when compared to both lean (p < 0.0001) and
obese (p = 0.004) controls but also when compared to
patients with liver steatosis (p = 0.024) (Fig. 1e).
Taken together, these results suggest that NE concen-
trations are up-regulated in our cohort of patients with
type 2 diabetes.
In order to investigate this further, we tried to divide
our T2DM cohort based on parameters that could
Table 2 Characteristics of the 41 patients with biopsy-diagnosed
NAFLD
Variable
Gender(M/F) 23/18
Age (years) 50 ± 11
BMI (kg/m2) 31.23 ± 5.76
Data is expressed as mean ± SD. BMI body mass index
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Fig. 2 PR3 and NE liver concentrations in patients biopsy-diagnosed with NAFLD. Assessment of NAFLD progression: patients with a NAFLD score
(NAS) (Brunt et al. 2011) between 0 and 2 were considered without NASH, patients with a NAFLD score between 3 and 4 were considered borderline
and patients with a score≥ 5 were diagnosed with NASH. Assessment of fibrosis stage (Brunt scale): patients with a fibrosis score of 1–2 were
considered as having mild fibrosis and patients with a fibrosis score of 3–4 were considered as having severe fibrosis. a PR3 concentrations in the liver
of patients with different NAS. b NE concentrations in the liver of patients with different NAS. c PR3 concentrations in the liver of patients with
different fibrosis scores. d NE concentrations in the liver of patients with different fibrosis scores. Data is represented as mean ± SEM. NS= p > 0.05
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indirectly reflect their degree of insulin sensitivity. First,
we divided the cohort into two groups, those receiving
insulin and those receiving anti-diabetes treatment other
than insulin. NE plasma concentrations were signifi-
cantly lower (p = 0.003) in patients that didn’t use insulin
versus patients that were also using insulin (Fig. 3a).
Since patients that use insulin probably have a higher
degree of insulin resistance these findings suggest that
NE concentrations in plasma could associate with the
levels of insulin resistance. Second, we divided the
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Fig. 3 PR3, NE and AAT plasma concentrations in patients with type 2 diabetes. a NE plasma concentrations in patients that didn't use insulin
drugs versus patients that also used insulin. b NE plasma concentrations between patients with well controlled glycaemia versus patients with a
poor control of glycaemia. c PR3 plasma concentrations in patients that didn't use insulin versus patients that also used insulin. d PR3 plasma
concentrations between patients with well controlled glycaemia versus patients with a poor control of glycaemia. e AAT plasma concentrations
in patients that didn't use insulin versus patients that also used insulin. f AAT plasma concentrations between patients with well controlled
glycaemia versus patients with a poor control of glycaemia. Data is represented as mean ± SEM. **p < 0.01, NS= p > 0.05
Mirea et al. Molecular Medicine           (2019) 25:16 Page 7 of 10
patients based on glucose control as reflected by their
HbA1c (glycated hemoglobin A1c) levels. Using a cutoff
level of 53 mmol/mol HbA1c (Inzucchi et al. 2015)
patients were divided in “well controlled” and “poorly
controlled”. In line with our previous observation, NE
plasma concentrations tended to be higher in the poorly
controlled patient group when compared to the
well-controlled patient group (p = 0.084) (Fig. 3b) while
PR3 and AAT concentrations were similar in these
groups (Fig. 3c-f ). Transformed data is available in
Additional file 6: Table S4.
These results suggest that NE plasma concentrations
are able to reflect – at least partly -the level of insulin
resistance in this type 2 diabetes cohort.
Discussion
This study extends earlier findings from animal experi-
ments and provides evidence for a role of PR3 and NE
in the inflammatory states associated with type 2
diabetes in general and with NAFLD in particular in
human subjects. This conclusion is based on the fact
that PR3 and NE plasma concentrations are elevated
both in individuals with liver steatosis and in patients
with type 2 diabetes when compared to lean healthy
individuals and obese individuals and are associated
with hsCRP, the marker of systemic inflammation.
Moreover, both PR3 and NE concentrations in the
liver tended to be higher in patients with advanced
stages of NAFLD when compared to patients with
mild disease.
Our results, indicating that NSPs are involved in
NAFLD and T2DM, are in line with previous reports.
Mansuy-Aubert and co-workers elegantly showed that
increased NE activity and decreased AAT serum concen-
trations contribute to the development of obesity, insulin
resistance and liver steatosis in animal models
(Mansuy-Aubert et al. 2013). Moreover, they showed an
imbalance between AAT serum concentrations and NE
activity in human obese subjects (Mansuy-Aubert et al.
2013). Another study, performed by Zang and
co-workers, showed an increased concentration of NE
and a decreased concentration of AAT in the serum of
NAFLD patients when compared to healthy individuals.
Additionally, they showed an increased NE/AAT ratio in
the advanced stages of NAFLD with a good sensitivity
and specificity to predict NASH (Zang et al. 2016).
Besides the role of NE in the development of
obesity-induced NAFLD and insulin resistance, our
group has shown an important role for PR3 as well in
these conditions in a mouse model of high-fat-
diet-induced obesity (Toonen et al. 2016). In the present
study we show for the first time a role for PR3 in
NAFLD and type 2 diabetes in human subjects. More-
over, we show increased ratios PR3/AAT, respectively
NE/AAT in the liver steatosis and type 2 diabetes
groups when compared to the control groups,
suggesting a deficiency in the production of AAT as a
response to PR3, respectively NE plasma concentra-
tions in these conditions. Of note, AAT concentra-
tions were similar between individuals with type 2
diabetes and lean healthy individuals. This increase in
AAT concentrations in obese individuals with type 2
diabetes could be related to the high concentrations
of hsCRP that can up-regulate AAT production
(Ottaviani et al. 2011). All together, our study shows
that an imbalance between NSPs concentrations and
their natural inhibitor, AAT, is present in obesity-as-
sociated metabolic conditions.
A limitation of our study was the lack of liver biop-
sies in our cohort of 271 obese individuals and a rela-
tively small number of patients with biopsy-diagnosed
NAFLD. Moreover, type 2 diabetes patients have also
an increased risk to develop NAFLD, so liver biopsies
in our cohort of 401 type 2 diabetes patients could
have helped us differentiate the NSPs concentrations
in T2DM alone versus T2DM that associate NAFLD
and understand better the variation of NSPs in these
two diseases. Further studies, using a larger cohort of
patients with biopsy-diagnosed NAFLD, comparing
not only NSPs concentrations but also enzymatic ac-
tivity in plasma and liver, would help elucidate the
role of these proteases in NAFLD. It would be also
interesting to assess whether NSPs concentration in
plasma or NSPs to AAT ratios could reflect the ad-
vanced stages of NAFLD and could be used as
non-invasive markers for advanced stages of the
disease.
Since PR3 and NE are able to activate cytokines
and modulate the immune response (Pham 2006) they
might play an important role in the development of
inflammation in NAFLD and the progression to
NASH. Also, due to the fact that they are able to
process extracellular matrix and activate pro-fibrotic
cytokines such as IL-1β and IL-33 (Interleukin-33)
(Gieling et al. 2009; Marvie et al. 2010), PR3 and NE
might play an important role in the mechanisms of
liver fibrosis. All these characteristics make PR3 and
NE potential candidates as therapeutic targets in
NAFLD. One potential therapeutic agent in this
respect could be alpha-1 antitrypsin.
Conclusion
In this study we show that both PR3 and NE plasma
concentrations are associated to obesity-induced meta-
bolic disorders. Further studies are needed to explore if
these proteases could be used as non-invasive markers
for NAFLD and/or type 2 diabetes.
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